In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Wave of Success for Cambridge Heart

Executive Summary

For years, Cambridge Heart has been in an almost missionary mode. Since its founding in 1990, it has spent millions on R&D and sustained steady losses. But it finally looks like Cambridge Heart is well on the way to answering the two key questions for medical technology developers: clinical relevance and reimbursement. On March 21, the US Centers for Medicare & Medicaid Services issued a national coverage decision for Cambridge Heart's Microvolt T-Wave Alternans test for patients at risk of sudden cardiac death,
Advertisement

Related Content

AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness
Headlines Obscure Robust Year for Devices in 2006
Risk Stratification for ICDs: The Debate Rages On
Risk Stratification for ICDs: The Debate Rages On
Case Study in Resuscitation: Can New Data Help Cambridge Heart?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002740

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel